Navigation Links
Orbsen Therapeutics' NEPHSTROM Clinical Trial Underway at Four European Union Locations
Date:10/3/2018

Orbsen Therapeutics, a biotechnology company focused on the discovery, development and commercialization of first-in-class stromal cell immunotherapies, announced that ORBCEL-M™, a second generation stromal cell immunotherapy, currently is being administered to patients with type 2 diabetes and progressive diabetic kidney disease in a four-site, pan-European Phase I/II clinical trial.

“We are pleased the NEPHSTROM clinical trial has commenced and that randomized diabetic patients with kidney disease whose previous therapies failed now are receiving ORBCEL-M immunotherapy,” said Dr. Larry Couture, CEO of Orbsen Therapeutics. “The study may be a breakthrough moment for patients with end-stage renal disease caused by diabetes.”

Orbsen’s patented allogeneic ORBCEL-M yields nearly 100 percent pure stromal cells, a significant increase in purity when compared to first generation stromal cell therapies. The NEPHSTROM study aims to prove whether the purer stromal cells in ORBCEL-M will be more effective in the prevention and treatment of diabetic kidney disease. Up to 40 percent of people with diabetes will develop kidney disease. Many will require a kidney transplant or a lifetime of dialysis.

“It’s a privilege to have the first patients enrolled and receiving treatment at the Mario Negri Institute,” said Professor Giuseppe Remuzzi of the Mario Negri Institute in Bergamo, Italy, and the clinical trial’s lead investigator. “The complementary skills and expertise of the four participating European centers provide a critical network demonstrating the clinical feasibility of this innovative therapy and the opportunity for additional coordinated trials in diabetic patients with progressive kidney disease for whom new therapies are urgently needed.”

Professor Timothy O’Brien, founding Director at Orbsen Therapeutics and coordinator of the NEPHSTROM study noted, “In my clinical practice, I see hundreds of patients with diabetic kidney disease who face the unpleasant possibility of dialysis or kidney transplantation. The outcome of this clinical trial may give patients another alternative and new hope.”

ORBCEL-M performed well in pre-clinical models as a therapy for diabetic kidney disease demonstrating significant improvements in kidney function.

“Encouraged by the promising results of the pre-clinical models, we are optimistic taking ORBCEL-M to the next stage to further investigate the immunotherapy as a solution to slow or stop progressive diabetic kidney disease,” said Steve Elliman, Chief Scientific Officer at Orbsen Therapeutics. “On behalf of Orbsen, we are privileged to be engaged with some of the European Union’s leading researchers and institutions through NEPHSTROM.”

Funded by the European Union Horizon 2020 program, the €80 billion research and innovation initiative, the NEPHSTROM study is designed to enroll up to 48 patients in a double-blind and placebo-controlled study. Patients who receive the ORBCEL-M therapy will be given three separate escalating doses.

NEPHSTROM’s four primary research locations are:
The Mario Negri Institute, Bergamo, Italy
National University of Ireland, Galway, Galway, Ireland
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Belfast Health and Social Care Trust, Belfast, Northern Ireland

Orbsen’s proprietary ORBCEL™ technology is pioneering potential stromal cell treatments to address a variety of diseases including diabetic foot ulcers, Acute Respiratory Distress Syndrome, Primary Sclerosing Cholangitis and other inflammatory and autoimmune disorders.

For more information about Orbsen Therapeutics, visit http://www.orbsentherapeutics.com.

About Orbsen Therapeutics

Orbsen Therapeutics, Ltd. is a leading company in the development of regenerative medicine therapies across a range of diseases and medical conditions. Founded in 2006, Orbsen Therapeutics Ltd., is a privately held company led by global leaders in the field of regenerative medicine. The company, which spun-out from Ireland’s Regenerative Medicine Institute at the National University of Ireland, Galway, has developed proprietary technologies that enable the isolation of pure and allogeneic stromal cells from human tissues which can be purified from a single donor, expanded and frozen to generate multiple doses of a high-margin, “off-the-shelf” therapeutic product.

For more information visit: http://www.orbsentherapeutics.com

Read the full story at https://www.prweb.com/releases/orbsen_therapeutics_nephstrom_clinical_trial_underway_at_four_european_union_locations/prweb15809598.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Clinical Trial Investigates Multicolor Tattoo Removal in Fewer Treatments
2. Dr. Deborah French Shares Insight on Validation of Clinical LC-MS/MS in Educational Webinar
3. DNAnexus and QIAGEN Team Up in Education Webinar: Scaling End-to-End NGS Solutions for Clinical Diagnostics in the Cloud
4. The Regenerative Medicine Institute Concludes 2018 with their "Clinical Staff Program" and "Hands-On Stem Cell and Adipose Procedures and Aspirations Training"
5. The 5th Annual Mobile in Clinical Trials Event Presents Agenda for September 24, 2018
6. Annual Expedition Mt. Kinabalu Raises Awareness of a Duchenne Clinical Trial Bringing Treatments to Boys in Malaysia
7. 4Dx Announces Preliminary Clinical Trial Data at Prestigious World Lung Imaging Event
8. MedNet Solutions Announces Latest Release Of Its Award-Winning eClinical Solution
9. TapImmune Completes Scale-Up and GMP Manufacturing of TPIV 200 Vaccine to Supply Additional Phase 2 Clinical Trials
10. CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor
11. MedNet Solutions Named Most Outstanding eClinical Solutions Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2019)... SASKATOON, Canada (PRWEB) , ... February 12, 2019 ... ... immediately it will begin operating under its new name, KEYLEAF. The company ... more of its own plant-based extracts and ingredients as finished products under the ...
(Date:2/2/2019)... ... January 31, 2019 , ... ... , geared toward clinical operations executives and focusing on all facets of clinical ... effective project management, portfolio management, resource management, patient engagement, and more. , ...
(Date:1/25/2019)... ... January 24, 2019 , ... ... PhD, Assistant Professor of Microbiology at the Jackson Laboratory (JAX), to its Scientific ... world, Dr. Oh will bring to uBiome expertise in skin microbial interactions and ...
Breaking Biology News(10 mins):
(Date:1/30/2019)... , ... January 29, 2019 , ... ... (AskBio), today announced the dosing of the first patient in a phase 1/2 ... a serious disease associated with high morbidity and often leads to premature death. ...
(Date:1/30/2019)... WHITEHOUSE, N.J. (PRWEB) , ... January 30, 2019 ... ... brings together experts from pharma, academia and governmental agencies to discuss best practices ... Washington, DC from February 4-6. , At this year’s conference, Visikol will ...
(Date:1/28/2019)... SAN DIEGO (PRWEB) , ... January 28, 2019 ... ... proteins against libraries of low molecular weight compounds. In this early stage, false ... binding. At the same time, it is vital that screening techniques are highly ...
(Date:1/24/2019)... (PRWEB) , ... January 22, 2019 , ... ... since each trial has its own set of assumptions, and RFP creation and ... so evaluating bids is like comparing apples to oranges. These challenges can ultimately ...
Breaking Biology Technology: